Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 16, 2023, titled "Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 toproceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatmentof patients with advanced solid tumors and lymphomas".